Bringing two sentences together in the announcement:
"The high potency of Veyonda in blocking cytokine release from damaged tissue in the laboratory meant we were obliged to adopt a very cautious and methodical approach when being used for the first time in patients with poor lung function. The 1800 mg dose was deemed by the clinicians to be sufficiently well tolerated in patients with moderate COVID-19 disease to become the preferred dose."
So maybe not in severe cases. I'm sure that 1800mg was "the preferred dose" before the trial began, but we had to safely test its safety. I guess we'll need to wait on the data to judge if it was the on-site doctor's preferred dose as well. All going well so far.
- Forums
- ASX - By Stock
- NOX
- Ann: NOXCOVID Trial Advances to Final Stage
Ann: NOXCOVID Trial Advances to Final Stage, page-6
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
8.7¢ |
Change
-0.006(6.45%) |
Mkt cap ! $25.42M |
Open | High | Low | Value | Volume |
9.2¢ | 9.2¢ | 8.3¢ | $44.27K | 511.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 17000 | 8.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.0¢ | 22476 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 17000 | 0.087 |
1 | 21340 | 0.086 |
2 | 15601 | 0.085 |
4 | 134754 | 0.083 |
2 | 115000 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.090 | 22476 | 2 |
0.095 | 4200 | 1 |
0.096 | 35000 | 1 |
0.099 | 30800 | 2 |
0.100 | 312884 | 2 |
Last trade - 15.41pm 15/08/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online